Amplification of anticancer efficacy by co-delivery of doxorubicin and lonidamine with extracellular vesicles

References

• Cabeza L, Perazzoli G, Peña M, et al. (2020). Cancer therapy based on extracellular vesicles as drug delivery vehicles. J Controlled Release 327:296–315.
   PubMed Web of Science ®Google Scholar
• Chen C, Sun M, Wang J, et al. (2021). Active cargo loading into extracellular vesicles: highlights the heterogeneous encapsulation behaviour. J Extracell Vesicles 10:e12163.
   PubMed Web of Science ®Google Scholar
• Chen R, Xu X, Qian Z, et al. (2019). The biological functions and clinical applications of exosomes in lung cancer. Cell Mol Life Sci 76:4613–33.
   PubMed Web of Science ®Google Scholar
• Cruz A, Mota P, Ramos C, et al. (2020). Polyurea dendrimer folate-targeted nanodelivery of l-buthionine sulfoximine as a tool to tackle ovarian cancer chemoresistance. Antioxidants 9:133.
   Web of Science ®Google Scholar
• De Martino C, Malorni W, Accinni L, et al. (1987). Cell membrane changes induced by lonidamine in human erythrocytes and T lymphocytes, and Ehrlich ascites tumor cells. Exp Mol Pathol 46:15–30.
   PubMed Web of Science ®Google Scholar
• Eom YW, Kim MA, Park SS, et al. (2005). Two distinct modes of cell death induced by doxorubicin: apoptosis and cell death through mitotic catastrophe accompanied by senescence-like phenotype. Oncogene 24:4765–77.
   PubMed Web of Science ®Google Scholar
• Floridi A, Bruno T, Miccadei S, et al. (1998). Enhancement of doxorubicin content by the antitumor drug lonidamine in resistant Ehrlich ascites tumor cells through modulation of energy metabolism. Biochem Pharmacol 56:841–9.
   PubMed Web of Science ®Google Scholar
• Floridi A, Paggi MG, D'Atri S, et al. (1981a). Effect of lonidamine on the energy metabolism of Ehrlich ascites tumor cells. Cancer Research 41:4661.
   PubMed Web of Science ®Google Scholar
• Floridi A, Paggi MG, Marcante ML, et al. (1981b). Lonidamine, a selective inhibitor of aerobic glycolysis of murine tumor cells. J Natl Cancer Inst 66:497–9.
   PubMed Web of Science ®Google Scholar
• Gao Y, Qin Y, Wan C, et al. (2021). Small extracellular vesicles: a novel avenue for cancer management. Front Oncol 11:638357.
   PubMed Web of Science ®Google Scholar
• Garofalo M, Saari H, Somersalo P, et al. (2018). Antitumor effect of oncolytic virus and paclitaxel encapsulated in extracellular vesicles for lung cancer treatment. J Control Release 283:223–34.
   PubMed Web of Science ®Google Scholar
• Gaurav I, Thakur A, Iyaswamy A, et al. (2021). Factors affecting extracellular vesicles based drug delivery systems. Molecules 26:1544.
   PubMed Web of Science ®Google Scholar
• Guo L, Shestov AA, Worth AJ, et al. (2016). Inhibition of mitochondrial complex II by the anticancer agent lonidamine. J Biol Chem 291:42–57.
   PubMed Web of Science ®Google Scholar
• Guo M, Wu F, Hu G, et al. (2019). Autologous tumor cell–derived microparticle-based targeted chemotherapy in lung cancer patients with malignant pleural effusion. Sci Transl Med 11:eaat5690.
   PubMed Web of Science ®Google Scholar
• Ha D, Yang N, Nadithe V. (2016). Exosomes as therapeutic drug carriers and delivery vehicles across biological membranes: current perspectives and future challenges. Acta Pharm Sin B 6:287–96.
   PubMed Web of Science ®Google Scholar
• Hoshino A, Costa-Silva B, Shen TL, et al. (2015). Tumour exosome integrins determine organotropic metastasis. Nature 527:329–35.
   PubMed Web of Science ®Google Scholar
• Huang Y, Sun G, Sun X, et al. (2020). The potential of lonidamine in combination with chemotherapy and physical therapy in cancer treatment. Cancers 12:3332.
   PubMed Web of Science ®Google Scholar
• Huyan T, Li H, Peng H, et al. (2020). Extracellular vesicles – advanced nanocarriers in cancer therapy: progress and achievements. Int J Nanomedicine 15:6485–502.
   PubMed Web of Science ®Google Scholar
• Juan ME, Wenzel U, Daniel H, et al. (2008). Resveratrol induces apoptosis through ROS-dependent mitochondria pathway in HT-29 human colorectal carcinoma cells. J Agric Food Chem 56:4813–8.
   PubMed Web of Science ®Google Scholar
• Kalyanaraman B, Joseph J, Kalivendi S, et al. (2002). Doxorubicin-induced apoptosis: implications in cardiotoxicity. Molecular and Cellular Biochemistry 234/235:119–24.
   PubMed Web of Science ®Google Scholar
• Kamerkar S, LeBleu VS, Sugimoto H, et al. (2017). Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer. Nature 546:498–503.
   PubMed Web of Science ®Google Scholar
• Lee T, Lau T, Ng I. (2002). Doxorubicin-induced apoptosis and chemosensitivity in hepatoma cell lines. Cancer Chemother Pharmacol 49:78–86.
   PubMed Web of Science ®Google Scholar
• Li J, Ren Y, Yuan Y, et al. (2016). Preclinical PK/PD model for combined administration of erlotinib and sunitinib in the treatment of A549 human NSCLC xenograft mice. Acta Pharmacol Sin 37:930–40.
   PubMed Web of Science ®Google Scholar
• Li Y, Gao Y, Gong C, et al. (2018). A33 antibody-functionalized exosomes for targeted delivery of doxorubicin against colorectal cancer. Nanomedicine 14:1973–85.
   PubMed Web of Science ®Google Scholar
• Li YC, Fung KP, Kwok TT, et al. (2002). Mitochondrial targeting drug lonidamine triggered apoptosis in doxorubicin-resistant HepG2 cells. Life Sci 71:2729–40.
   PubMed Web of Science ®Google Scholar
• Liu Y, Zhang X, Zhou M, et al. (2017). Mitochondrial-targeting lonidamine-doxorubicin nanoparticles for synergistic chemotherapy to conquer drug resistance. ACS Appl Mater Interfaces 9:43498–507.
   PubMed Web of Science ®Google Scholar
• Mathieu M, Martin-Jaular L, Lavieu G, et al. (2019). Specificities of secretion and uptake of exosomes and other extracellular vesicles for cell-to-cell communication. Nat Cell Biol 21:9–17.
   PubMed Web of Science ®Google Scholar
• Mulcahy LA, Pink RC, Carter DRF. (2014). Routes and mechanisms of extracellular vesicle uptake. J Extracell Vesicles 3:24641.
   PubMedGoogle Scholar
• Nasongkla N, Bey E, Ren J, et al. (2006). Multifunctional polymeric micelles as cancer-targeted, MRI-ultrasensitive drug delivery systems. Nano Lett 6:2427–30.
   PubMed Web of Science ®Google Scholar
• Peng Y, Lu J, Li R, et al. (2021). Glucose and triphenylphosphonium co-modified redox-sensitive liposomes to synergistically treat glioma with doxorubicin and lonidamine. ACS Appl Mater Interfaces 13:26682–93.
   PubMed Web of Science ®Google Scholar
• Pi F, Binzel DW, Lee TJ, et al. (2018). Nanoparticle orientation to control RNA loading and ligand display on extracellular vesicles for cancer regression. Nat Nanotechnol 13:82–9.
   PubMed Web of Science ®Google Scholar
• Ping M, Mumper RJ. (2013). Paclitaxel nano-delivery systems: a comprehensive review. J Nanomed Nanotechnol 4:1000164.
   PubMedGoogle Scholar
• Prada I, Meldolesi J. (2016). Binding and fusion of extracellular vesicles to the plasma membrane of their cell targets. IJMS 17:1296.
   Web of Science ®Google Scholar
• Skotland T, Hessvik NP, Sandvig K, et al. (2019). Exosomal lipid composition and the role of ether lipids and phosphoinositides in exosome biology. J Lipid Res 60:9–18.
   PubMed Web of Science ®Google Scholar
• Sun B, Luo C, Cui W, et al. (2017). Chemotherapy agent-unsaturated fatty acid prodrugs and prodrug-nanoplatforms for cancer chemotherapy. J Control Release 264:145–59.
   PubMed Web of Science ®Google Scholar
• Sun Z, Xie H, Tang S, et al. (2015). Ultrasmall black phosphorus quantum dots: synthesis and use as photothermal agents. Angew Chem Int Ed Engl 54:11526–30.
   PubMed Web of Science ®Google Scholar
• Sung H, Ferlay J, Siegel RL, et al. (2021). Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71:209–49.
   PubMed Web of Science ®Google Scholar
• Swift LP, Rephaeli A, Nudelman A, et al. (2006). Doxorubicin-DNA adducts induce a non-topoisomerase II-mediated form of cell death. Cancer Res 66:4863–71.
   PubMed Web of Science ®Google Scholar
• Toffoli G, Hadla M, Corona G, et al. (2015). Exosomal doxorubicin reduces the cardiac toxicity of doxorubicin. Nanomedicine 10:2963–71.
   PubMed Web of Science ®Google Scholar
• Van den Boorn JG, Schlee M, Coch C, et al. (2011). SiRNA delivery with exosome nanoparticles. Nat Biotechnol 29:325–6.
   PubMed Web of Science ®Google Scholar
• Wang Y, Guo M, Lin D, et al. (2021). Docetaxel-loaded exosomes for targeting non-small cell lung cancer: preparation and evaluation in vitro and in vivo. Drug Deliv 28:1510–23.
   PubMed Web of Science ®Google Scholar
• Witwer KW, Wolfram J. (2021). Extracellular vesicles versus synthetic nanoparticles for drug delivery. Nat Rev Mater 6:103–6.
   PubMed Web of Science ®Google Scholar
• Xu J, Zhao Q, Jin Y, et al. (2014). High loading of hydrophilic/hydrophobic doxorubicin into polyphosphazene polymersome for breast cancer therapy. Nanomedicine 10:349–58.
   PubMed Web of Science ®Google Scholar
• Yong T, Wang D, Li X, et al. (2020). Extracellular vesicles for tumor targeting delivery based on five features principle. J Control Release 322:555–65.
   PubMed Web of Science ®Google Scholar
• Yong T, Zhang X, Bie N, et al. (2019). Tumor exosome-based nanoparticles are efficient drug carriers for chemotherapy. Nat Commun 10:1–16.
   PubMed Web of Science ®Google Scholar
• Yu L, Dong A, Guo R, et al. (2018). DOX/ICG coencapsulated liposome-coated thermosensitive nanogels for NIR-triggered simultaneous drug release and photothermal effect. ACS Biomater Sci Eng 4:2424–34.
   PubMed Web of Science ®Google Scholar
• Zhao J, Ye Z, Yang J, et al. (2020). Nanocage encapsulation improves antiepileptic efficiency of phenytoin. Biomaterials 240:119849.
   PubMed Web of Science ®Google Scholar
• Zheng Z, Li Z, Xu C, et al. (2019). Folate-displaying exosome mediated cytosolic delivery of siRNA avoiding endosome trapping. J Controlled Release 311–312:43–9.
   PubMed Web of Science ®Google Scholar